Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months

Regulatory T cell monitoring in severe eosinophilic asthma patients treated with mepolizumab

(2021) Laura Bergantini et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab

(2020) David J. Jackson et al.   DRUG SAFETY

Personalized Approach of Severe Eosinophilic Asthma Patients Treated with Mepolizumab and Benralizumab

(2020) Laura Bergantini et al.   INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY

Mepolizumab and Benralizumab in Severe Eosinophilic Asthma: Preliminary Results of a Proteomic Study

(2020) Lorenza Vantaggiato et al.   LUNG

Ceruloplasmin and oxidative stress in severe eosinophilic asthma patients treated with Mepolizumab and Benralizumab

(2020) Claudia Landi et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

Indirect treatment comparisons and biologics

(2019) David Mauger et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

The prevalence and disease burden of severe eosinophilic asthma in Japan

(2019) Tadao Nagasaki et al.   JOURNAL OF ASTHMA

The Cytokines of Asthma

(2019) Bart N. Lambrecht et al.   IMMUNITY

Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement

(2019) Brian L. Graham et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Anti-IL-5 therapy in patients with severe eosinophilic asthma – clinical efficacy and possible criteria for treatment response

(2018) Nora Drick et al.   BMC Pulmonary Medicine

Severe Asthma

(2018) Marek Lommatzsch et al.   Deutsches Arzteblatt International

Anti–IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison

(2018) William Busse et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis

(2018) Thomas B. Casale et al.   Journal of Allergy and Clinical Immunology-In Practice

Matching-adjusted indirect comparison of benralizumab versus interleukin-5 inhibitors for the treatment of severe asthma: a systematic review

(2018) Arnaud Bourdin et al.   EUROPEAN RESPIRATORY JOURNAL

Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial

(2018) William W Busse et al.   Lancet Respiratory Medicine

Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies

(2017) Frank C. Albers et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population

(2017) Marjan Kerkhof et al.   THORAX

Overlap of atopic, eosinophilic, and TH2-high asthma phenotypes in a general population with current asthma

(2016) Trung N. Tran et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels

(2016) Leif Bjermer et al.   CHEST

Comparison of anti-interleukin-5 therapies in patients with severe asthma: global and indirect meta-analyses of randomized placebo-controlled trials

(2016) Y. Cabon et al.   CLINICAL AND EXPERIMENTAL ALLERGY

Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial

(2016) Eugene R Bleecker et al.   LANCET

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial

(2016) J Mark FitzGerald et al.   LANCET

Economic Burden of Illness Among Patients with Severe Asthma in a Managed Care Setting

(2016) Benjamin Chastek et al.   Journal of Managed Care & Specialty Pharmacy

Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma

(2014) Elisabeth H. Bel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma

(2014) Hector G. Ortega et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prospective evaluation of current asthma control using ACQ and ACT compared with GINA criteria

(2011) Stephanie Korn et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Lung damage and airway remodelling in severe asthma

(2011) C. E. Brightling et al.   CLINICAL AND EXPERIMENTAL ALLERGY